Proteomic approaches in drug discovery and development

International Review of Neurobiology

Volumn 61, Issue , 2004, Pages 97-126

  Soares, Holly D ^a   Williams, Stephen A ^a   Snyder, Peter J ^a   Gao, Feng ^a   Stiger, Tom ^a   Rohlff, Christian ^b   Herath, Athula ^b   Sunderland, Trey ^c   Putnam, Karen ^c   White, W Frost ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b Oxford Glycosciences   (United Kingdom)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CASE CONTROL STUDY; DRUG DESIGN; HUMAN; METABOLISM; METHODOLOGY; PHARMACEUTICS; PROTEOMICS; REVIEW;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DRUG DESIGN; HUMANS; PROTEOMICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 16544391825     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(04)61005-1     Document Type: Article

References (101)

1. Aarts, M., Liu, Y., Liu, L., Besshoh, S., Arundine, M., Gurd, J. W., Wang, Y. T., Salter, M. W., and Tymianski, M. (2002). Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science 298(5594), 846-850.
2. Adam, G. C., Sorensen, E. J., and Cravatt, B. F. (2002a). Chemical strategies for functional proteomics. Mol. Cell Proteomics 1(10), 781-790.
3. Adam, G. C., Sorensen, E. J., and Cravatt, B. F. (2002b). Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype. Nat. Biotechnol. 20(8), 805-809.
4. Aebersold, R. (2003). A mass spectrometric journey into protein and proteome research. J. Am. Soc. Mass. Spectrom. 14, 685-695.
5. Amess, B., and Tolkovsky, A. M. (1995). Electrophoresis 16, 1255-1267.
6. Bandara, L. R., Kelly, M. D., Lock, E. A., and Kennedy, S. (2003). A correlation between a proteomic evaluation and conventional measurements in the assessment of renal proximal tubular toxicity. Toxicol. Sci. 73(1), 195-206.
7. Bartel, P. L., Roecklein, J. A., SenGupta, D., and Fields, S. (1996). A protein linkage map of Escherichia coli bacteriophage T7. Nat. Genet. 12(1), 72-77.
8. Blennow, K., Davidsson, P., Wallin, A., and Ekman, R. (1995). Chromogranin A in cerebrospinal fluid: A biochemical marker for synaptic degeneration in Alzheimer's disease? Dementia 6(6), 306-311.
9. Boguski, M. S., and McIntosh, M. W. (2003). Biomedical informatics for proteomics. Nature 422(6928), 233-237.
10. Borodovsky, A., Ovaa, H., Kolli, N., Gan-Erdene, T., Wilkinson, K. D., Ploegh, H. L., and Kessler, B. M. (2002). Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9(10), 1149-1159.
11. Brindle, J. T., Antti, H., Holmes, E., Tranter, G., Nicholson, J. K., Bethell, H. W., Clarke, S., Schofield, P. M., McKilligin, E., Mosedale, D. E., and Grainger, D. J. (2002). Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat. Med. 8(12), 1439-1444.
12. Brindle, J. T., Nicholson, J. K., Schofield, P. M., Grainger, D. J., and Holmes, E. (2003). Application of chemometrics to 1H NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 128(1), 32-36.
13. Brookmeyer, R., and Gray, S. (2000). Methods for projecting the incidence and prevalence of chronic diseases in aging populations: Application to Alzheimer's disease. Stat. Med. 19(11-12), 1481-1493.
14. Chakravarti, D. N., Chakravarti, B., and Moutsatsos, I. (2002). Informatic tools for proteome profiling. Biotechniques (Suppl.), 4-10, 12-15.
15. Chang, C. Y., Norris, J. D. Jansen, M., Huang, H. J., and McDonnell, D. P. (2003). Application of random peptide phage display to the study of nuclear hormone receptors. Methods Enzymol. 364, 118-142.
16. Chaurand, P., Fouchecourt, S., DaGue, B. B., Xu, B. J., Reyzer, M. L., Orgebin-Crist, M. C., and Caprioli, R. M. (2003). Profiling and imaging proteins in the mouse epididymis by imaging mass spcctrometry. Proteomics 3(11), 2221-2239.
17. Chaurand, P., Schwartz, S. A., and Caprioli, R. M. (2002). Imaging mass spectrometry. A new tool to investigate the spatial organization of peptides and proteins in mammalian tissue sections. Curr. Opin. Chem. Biol. 6(5), 676-681.
18. Clark, B. F. (1981). Towards a total human protein map. Nature 292(5823), 491-492.
19. Davidsson, P., Sjogren, M., Andreasen, N., Lindbjer, M., Nilsson, C. L., Westman-Brinkmalm, A., and Blennow, K. (2002). Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res. Mol. Brain Res. 109(1-2), 128-133.
20. DiMasi, J. A., Hansen, R. W., and Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. J. Health Econ. 22(2), 151-185.
21. DiMasi, J. A., Hansen, R. W., Grabowski, H. G., and Lasagna, L. (1991). Cost of innovation in the pharmaceutical industry. J. Health Econ. 10(2), 107-142.
22. Doody, R. S., Massman, P., and Dunn, J. K. (2001). A method for estimating progression rates in Alzheimer disease. Arch. Neurol. 58(3), 449-454.
23. Emmerling, M. R., Watson, M. D., Raby, C. A., and Spiegel, K. (2000). The role of complement in Alzheimer's disease pathology. Biochim. Biophys. Acta. 1502(1), 158-171.
24. Espina, V., Mehta, A. I., Winters, M. E., Calvert, V., Wulfkuhle, J., Petricoin, E. F., III, and Liotta, L. A. (2003). Protein microarrays: Molecular profiling technologies for clinical specimens. Proteomics 3(11), 2091-2100.
25. Fenyo, D., and Beavis, R. C. (2002). Informatics and data management in proteomics. Trends Biotechnol. 20(Suppl. 12), S35-S38.
26. Fields, S., and Song, O. (1989). A novel genetic system to detect protein-protein interactions. Nature 340(6230), 245-246.
27. Flajolet, M., Rotondo, G., Daviet, L., Bergametti, F., Inchauspe, G., Tiollais, P., Transy, C., and Legrain, P. (2000). A genomic approach of the hepatitis C virus generates a protein interaction map. Gene 242(1-2), 369-379.
28. Fuh, G., Pisabarro, M. T., Li, Y., Quan, C., Lasky, L. A., and Sidhu, S. S. (2000). Analysis of PDZ domain-ligand interactions using carboxyl-terminal phage display. J. Biol. Chem. 275(28), 21486-21491.
29. Gerlt, J. A. (2002). "Fishing" for the functional proteome Nat. Biotechnol. 20(8), 786-787.
30. Griffin, J. L. (2003). Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr. Opin. Chem. Biol. 7(5), 648-654.
31. Griffin, J. L., Cemal, C. K., and Pook, M. A. (2003). Defining a metabolic phenotype in the brain of a transgenic mouse model of spinocerebellar ataxia 3. Physiol. Genomics. 16, 16.
32. Grubb, R. L., Calvert, V. S., Wulkuhle, J. D., Paweletz, C. P., Linehan, W. M., Phillips, J. L., Chuaqui, R., Valasco, A., Gillespie, J., Emmert-Buck, M., Liotta, L. A., and Petricoin, E. F. (2003). Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3(11), 2142-2146.
33. Gygi, S. P., and Aebersold, R. (2000). Mass spectrometry and proteomics. Curr. Opin. Chem. Biol. 4(5), 489-494.
34. Gygi, S. P., Corthals, G. L., Zhang, Y., Rochon, Y., and Aebersold, R. (2000). Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc. Natl. Acad. Sci. USA 97(17), 9390-9395.
35. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., and Aebersold, R. (1999). Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17(10), 994-999.
36. Haab, B. B. (2003). Methods and applications of antibody microarrays in cancer research. Proteomics 3(11), 2116-2122.
37. Hagenstein, M. C., Mussgnug, J. H., Lotte, K., Plessow, R., Brockhinke, A., Kruse, O., and Sewald, N. (2003). Affinity-based tagging of protein families with reversible inhibitors: A concept for functional proteomics. Angew Chem. Int. Ed. Eng. 42(45), 5635-5638.
38. Hanash, S. (2003). The emerging field of protein microarrays. Proteomics 3(11), 2075.
39. Harris, R. A., Yang, A., Stein, R. C., Lucy, K., Brusten, L., Herath, A., Parekh, R., Waterfield, M. D., O'Hare, M. J., Neville, M. A., Page, M. J., and Zvelebil, M. J. (2002). Cluster analysis of an extensive human breast cancer cell line protein expression map database. Proteomics 2(2), 212-223.
40. Hoogenboom, H. R., de Bruine, A. P., Hufton, S. E., Hoet, R. M., Arends, J. W., and Roovers, R. C. (1998). Antibody phage display technology and its applications. Immunotechnology 4(1), 1-20.
41. Hufton, S. E., Moerkerk, P. T., Meulemans, E. V., de Bruine, A., Arends, J. W., and Hoogenboom, H. R. (1999). Phage display of cDNA repertoires: The pVI display system and its applications for the selection of immunogenic ligands. J. Immunol. Methods 231(1-2), 39-51.
42. Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., and Engelhard, V. H. (1992). Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255(5049), 1261-1263.
43. Jang, J. H., and Hanash, S. (2003). Profiling of the cell surface proteome. Proteomics 3(10), 1947-1954.
44. Jarvik, J. W., Fisher, G. W., Shi, C., Hennen, L., Hauser, C., Adler, S., and Berget, P. B. (2002). In vivo functional proteomics: Mammalian genome annotation using CD-tagging. Biotechniques 33(4), 852-854, 856, 858-860 passim.
45. Jensen, M., Schroder, J., Blomberg, M., Engvall, B., Pantel, J., Ida, N., Basun, H., Wahlund, L. O., Werle, E., Jauss, M., Beyreuther, K., Lannfelt, L., and Hartmann, T. (1999). Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann. Neurol. 45(4), 504-511.
46. Jessani, N., Liu, Y., Humphrey, M., and Cravatt, B. F. (2002). Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. USA 99(16), 10335-10340.
47. Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., Watanabe, M., Tomidokoro, Y., Shizuka, M., Mizushima, K., Nakamura, T., Igeta, Y., Ikeda, Y., Amari, M., Kawarabayashi, T., Ishiguro, K., Harigaya, Y., Wakabayashi, K., Okamoto, K., Hirai, S., and Shoji, M. (1998). Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: A study in Japan. Ann. Neurol. 44(1), 17-26.
48. Kaufmann, W. A., Bamas, U., Kumpel, C., Nowakowski, K., DeCol, C., Gurka, P., Ransmayr, G., Hinterhuber, H., Winkler, H., and Marksteiner, J. (1998). Synaptic loss reflected by secretoneurin-like immunoreactivity in the human hippocampus in Alzheimer's disease. Eur. J. Neurosci. 10(3), 1084-1094.
49. Kenyon, G. L., DeMarini, D. M., Fuchs, E., Galas, D. J., Kirsch, J. F., Leyh, T. S., Moos, W. H., Petsko, G. A., Ringe, D., Rubin, G. M., and Sheahan, L. C. (2002). Defining the mandate of proteomics in the post-genomics era: Workshop report. Mol. Cell Proteomics 1(10), 763-780.
50. Kim, T., Tao-Cheng, J. H., Eiden, L. E., and Peng Loh, Y. (2003). The role of chromogranin A and the control of secretory granule genesis and maturation. Trends Endocrinol. Metab. 14(2), 56-57.
51. Klose, J. (1975). Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 26(3), 231-243.
52. Kozarich, J. W. (2003). Activity-based proteomics: Enzyme chemistry redux. Curr. Opin. Chem. Biol. 7(1), 78-83.
53. Lathrop, J. T., Anderson, N. L., Anderson, N. G., and Hammond, D. J. (2003). Therapeutic potential of the plasma proteome. Curr. Opin. Mol. Ther. 5(3), 250-257.
54. Le Blanc, J. C., Hager, J. W., Ilisiu, A. M., Hunter, C., Zhong, F., and Chu, I. (2003). Unique scanning capabilities of a new hybrid linear ion trap mass spectrometer (QTRAP) used for high sensitivity proteomics applications. Proteomics 3(6), 859-869.
55. Li Kw, K., Hornshaw, M. P., Van Der Schors, R. C., Watson, R., Tate, S., Casetta, B., Jimenez, C. R., Gouwenberg, Y., Gundelfinger, E. D., Smalla, K. H., and Smit, A. B. (2003). Proteomics analysis of rat brain postsynaptic density: Implications of the diverse protein functional groups for the integration of synaptic physiology. J. Biol. Chem. 7, 7.
56. Lill, J. (2003). Proteomic tools for quantitation by mass spectrometry. Mass. Spectrom. Rev. 22(3), 182-194.
57. Lin, D., Tabb, D. L., and Yates, J. R., III (2003). Large-scale protein identification using mass spectrometry. Biochim. Biophys. Acta. 1646, 1-10.
58. Link, A. J., Eng, J., Schieltz, D. M., Carmack, E., Mize, G. J., Morris, D. R., Garvik, B. M., and Yates, J. R., III (1999). Direct analysis of protein complexes using mass spectrometry. Nat. Biotechnol. 17(7), 676-682.
59. Linker, G., Mirza, N., Meyer, M., Putnam, K. T., and Sunderland, T. (2002). Fine-needle, negative-pressure lumbar puncture: A safe technique for collecting CSF. Neurology 59(12), 2008-2009.
60. Liu, Y., Patricelli, M. P., and Cravatt, B. F. (1999). Activity-based protein profiling: The serine hydrolases. Proc. Natl. Acad. Sci. USA 96, 14964-14699.
61. Lo, L. C., Pang, T. L., Kuo, C. H., Chiang, Y. L., Wang, H. Y., and Lin, J. J. (2002). Design and synthesis of class-selective activity probes for protein tyrosine phosphatases. J. Proteome Res. 1(1), 35-40.
62. Marksteiner, J., Kaufmann, W. A., Gurka, P., and Humpel, C. (2002). Synaptic proteins in Alzheimer's disease. J. Mol. Neurosci. 18(1-2), 53-63.
63. Marksteiner, J., Lechner, T., Kaufmann, W. A., Gurka, P., Humpel, C., Nowakowski, C., Maier, H., and Jellinger, K. A. (2000). Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer's disease. Acta. Neuropathol. (Berl) 100(2), 205-212.
64. McCraith, S., Holtzman, T., Moss, B., and Fields, S. (2000). Genome-wide analysis of vaccinia virus protein-protein interactions. Proc. Natl. Acad. Sci. USA 97(9), 4879-4884.
65. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34(7), 939-944.
66. O'Farrell, P. Z., Goodman, H. M., and O'Farrell, P. H. (1977). High resolution two-dimensional electrophoresis of basic as well as acidic proteins. Cell 12(4), 1133-1141.
67. Ong, S. E., Foster, L. J., and Mann, M. (2003). Mass spectrometric-based approaches in quantitative proteomics. Methods 29, 124-130.
68. Page, M. J., Amess, B., Townsend, R. R., Parekh, R., Herath, A., Brusten, L., Zvelebil, M. J., Stein, R. C., Waterfield, M. D., Davies, S. C., and O'Hare, M. J. (1999). Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplastics. Proc. Natl. Acad. Sci. USA 96(22), 12589-12594.
69. Patricelli, M. P., Giang, D. K., Stamp, L. M., and Burbaum, J. J. (2001). Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active stie-directed probes. Proteomics 1, 1067-1071.
70. Pieper, R., Gatlin, C. L., Makusky, A. J., Russo, P. S., Schatz, C. R., Miller, S. S., Su, Q., McGrath, A. M., Estock, M. A., Parmar, P. P., Zhao, M., Huang, S. T., Zhou, J., Wang, F., Esquer-Blasco, R., Anderson, N. L., Taylor, J., and Steiner, S. (2003). The human serum proteome: Display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics 3(7), 1345-1364.
71. Rain, J. C., Selig, L., De Reuse, H., Battaglia, V., Reverdy, C., Simon, S., Lenzen, G., Petel, F., Wojcik, J., Schachter, V., Chemama, Y., Labigne, A., and Legrain, P. (2001). The protein-protein interaction map of Helicobacter pylori. Nature 409(6817), 211-215.
72. Reichert, J. M. (2003). Trends in development and approval times for new therapeutics in the United States. Nat. Rev. Drug Discov. 2(9), 695-702.
73. Roberts, S. A. (2003). Drug metabolism and pharmacokinetics in drug discovery. Curr. Opin. Drug Discov. Devel. 6(1), 66-80.
74. Robertson, D. G., Reily, M. D., Albassam, M., and Dethloff, L. A. (2001). Metabonomic assessment of vasculitis in rats. Cardiovasc. Toxicol. 1(1), 7-19.
75. Rosen, V. M., Bergeson, J. L., Putnam, K., Harwell, A., and Sunderland, T. (2002). Working memory and apolipoprotein E: What's the connection? Neuropsychologia 40(13), 2226-2233.
76. Sanchez, J. C., Rouge, V., Pisteur, M., Ravier, F., Tonella, L., Moosmayer, M., Wilkins, M. R., and D.F., H. (1997). Electrophoresis 18, 324-327.
77. Sekar, R. B., and Periasamy, A. (2003). Fluorescence resonance energy transfer (FRET) microscopy imaging of live cell protein localizations. J. Cell Biol. 160(5), 629-633.
78. Shen, Y., and Meri, S. (2003). Yin and Yang: Complement activation and regulation in Alzheimer's disease. Prog. Neurobiol. 70(6), 463-472.
79. Sidhu, S. S., Bader, G. D., and Boone, C. (2003). Functional genomics of intracellular peptide recognition domains with combinatorial biology methods. Curr. Opin. Chem. Biol. 7(1), 97-102.
80. Skelton, N. J., Koehler, M. F., Zobel, K., Wong, W. L., Yeh, S., Pisabarro, M. T., Yin, J. P., Lasky, L. A., and Sidhu, S. S. (2003). Origins of PDZ domain ligand specificity. Structure determination and mutagenesis of the Erbin PDZ domain. J. Biol. Chem. 278(9), 7645-7654.
81. Smith, R. D. (2002). Trends in mass spectrometry instrumentation for proteomics. Trends Biotechnol. 20(Suppl. 12), S3-S7.
82. Stoeckli, M., Chaurand, P., Hallahan, D. E., and Caprioli, R. M. (2001). Imaging mass spectrometry: A new technology for the analysis of protein expression in mammalian tissues. Nat. Med. 7(4), 493-496.
83. Stoeckli, M., Staab, D., Staufenbiel, M., Wiederhold, K. H., and Signor, L. (2002). Molecular imaging of amyloid beta peptides in mouse brain sections using mass spectrometry. Anal. Biochem. 311(1), 33-39.
84. Stupka, E. (2002). Large-scale open bioinformatics data resources. Curr. Opin. Mol. Ther. 4(3), 265-274.
85. Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., Bartko, J. J., and Cohen, R. M. (2003). Decreased beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289(16), 2094-2103.
86. Tang, N., Tornatore, P., and Weinberger, S. R. (2004). Current developments in SELDI affinity technology. Mass. Spectrom. Rev. 23(1), 34-44.
87. Tapiola, T., Pirttila, T., Mikkonen, M., Mehta, P. D., Alafuzoff, I., Koivisto, K., and Soininen, H. (2000). Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci. Lett. 280(2), 119-122.
88. Taupenot, L., Harper, K. L., and O'Connor, D. T. (2003). The chromogranin-secretogranin family. N. Engl. J. Med. 348(12), 1134-1149.
89. Taylor, C. F., Paton, N. W., Garwood, K. L., Kirby, P. D., Stead, D. A., Yin, Z., Deutsch, E. W., Selway, L., Walker, J., Riba-Garcia, I., Mohammed, S., Deery, M. J., Howard, J. A., Dunkley, T., Aebersold, R., Kell, D. B., Lilley, K. S., Roepstorff, P., Yates, J. R., 3rd, Brass, A., Brown, A. J., Cash, P., Gaskell, S. J., Hubbard, S. J., and Oliver, S. G. (2003). A systematic approach to modeling, capturing, and disseminating proteomics experimental data. Nat. Biotechnol. 21(3), 247-254.
90. Templin, M. F., Stoll, D., Schwenk, J. M., Potz, O., Kramer, S., and Joos, T. O. (2003). Protein microarrays: Promising tools for proteomic research. Proteomics 3(11), 2155-2166.
91. Todd, P. J., Schaaff, T. G., Chaurand, P., and Caprioli, R. M. (2001). Organic ion imaging of biological tissue with secondary ion mass spectrometry and matrix-assisted laser desorption/ionization. J. Mass. Spectrom. 36(4), 355-369.
92. Uetz, P. (2002). Two-hybrid arrays. Curr. Opin. Chem. Biol. 6(1), 57-62.
93. Uetz, P., Giot, L., Cagney, G., Mansfield, T. A., Judson, R. S., Knight, J. R., Lockshon, D., Narayan, V., Srinivasan, M., Pochart, P., Qureshi-Emili, A., Li, Y., Godwin, B., Conover, D., Kalbfleisch, T., Vijayadamodar, G., Yang, M., Johnston, M., Fields, S., and Rothberg, J. M. (2000). A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae. Nature 403(6770), 623-627.
94. VanBogelen, R. A. (1999). Generating a bacterial genome inventory. Identifying 2-D spots by comigrating products of the genome on 2-D gels. Methods Mol. Biol. 112, 423-429.
95. Walhout, A. J., Boulton, S. J., and Vidal, M. (2000). Yeast two-hybrid systems and protein interaction mapping projects for yeast and worm. Yeast 17(2), 88-94.
96. Watkins, S. M., and German, J. B. (2002). Metabolomics and biochemical profiling in drug discovery and development. Curr. Opin. Mol. Ther. 4(3), 224-228.
97. Wiedermann, C. J. (2000). Secretoneurin: A functional neuropeptide in health and disease. Peptides 21(8), 1289-1298.
98. Wouters, F. S., Verveer, P. J., and Bastiaens, P. I. (2001). Imaging biochemistry inside cells. Trends Cell Biol. 11(5), 203-211.
99. Wu, C. C., and Yates, J. R., 3rd (2003). The application of mass spectrometry to membrane proteomics. Nat. Biotechnol. 21(3), 262-267.
100. Zeytun, A., Jeromin, A., Scalettar, B. A., Waldo, G. S., and Bradbury, A. R. (2003). Fluorobodies combine GFP fluorescence with the binding characteristics of antibodies. Nat. Biotechnol. 21(12), 1473-1479.
101. Zozulya, S., Lioubin, M., Hill, R. J., Abram, C., and Gishizky, M. L. (1999). Mapping signal transduction pathways by phage display. Nat. Biotechnol. 17(12), 1193-1198.